This is potentially linked to increased levels of a compound called TMAO in the blood [14]
formulated a special combination of vitamin C (180 mg), vitamin E (30 mg), zinc (15 mg), selenium (50 mg), LC tartarate (400 mg), folic acid (200 g) and coenzyme-Q10 (40 mg)
The condition is not merely the result of individual choices
It represents a defined peptide fraction originally characterised from thymic tissue and subsequently produced in synthetic form for research applications
Patients with multiple comorbidities, such as atrial fibrillation or venous thromboembolism, are at higher risk of bleeding when using DOACs in combination with GLP-1R agonists
Sounds like big risks for very little potential reward Join the conversation